TET vs. VCT, SCPA, ESNT, SYNT, ZTF, IOF, WCH, ITX, DCTA, and HAYD
Should you be buying Treatt stock or one of its competitors? The main competitors of Treatt include Victrex (VCT), Scapa Group (SCPA), Essentra (ESNT), Synthomer (SYNT), Zotefoams (ZTF), Iofina (IOF), Wilmcote Holdings plc (WCH.L) (WCH), Itaconix (ITX), Directa Plus (DCTA), and Haydale Graphene Industries (HAYD). These companies are all part of the "specialty chemicals" industry.
Treatt vs.
Treatt (LON:TET) and Victrex (LON:VCT) are both small-cap basic materials companies, but which is the better stock? We will compare the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, earnings, community ranking, profitability, valuation, institutional ownership and risk.
In the previous week, Treatt and Treatt both had 3 articles in the media. Victrex's average media sentiment score of 1.26 beat Treatt's score of -0.12 indicating that Victrex is being referred to more favorably in the news media.
Treatt has a beta of 1.02, suggesting that its share price is 2% more volatile than the S&P 500. Comparatively, Victrex has a beta of 0.69, suggesting that its share price is 31% less volatile than the S&P 500.
50.9% of Treatt shares are owned by institutional investors. Comparatively, 97.1% of Victrex shares are owned by institutional investors. 13.4% of Treatt shares are owned by company insiders. Comparatively, 1.6% of Victrex shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Treatt currently has a consensus price target of GBX 650, suggesting a potential upside of 94.22%. Victrex has a consensus price target of GBX 1,425, suggesting a potential upside of 58.86%. Given Treatt's stronger consensus rating and higher probable upside, research analysts plainly believe Treatt is more favorable than Victrex.
Victrex received 347 more outperform votes than Treatt when rated by MarketBeat users. However, 68.97% of users gave Treatt an outperform vote while only 63.61% of users gave Victrex an outperform vote.
Victrex has higher revenue and earnings than Treatt. Treatt is trading at a lower price-to-earnings ratio than Victrex, indicating that it is currently the more affordable of the two stocks.
Treatt pays an annual dividend of GBX 8 per share and has a dividend yield of 2.4%. Victrex pays an annual dividend of GBX 60 per share and has a dividend yield of 6.7%. Treatt pays out 43.2% of its earnings in the form of a dividend. Victrex pays out 170.5% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future.
Victrex has a net margin of 10.81% compared to Treatt's net margin of 7.88%. Treatt's return on equity of 8.09% beat Victrex's return on equity.
Summary
Victrex beats Treatt on 10 of the 18 factors compared between the two stocks.
Get Treatt News Delivered to You Automatically
Sign up to receive the latest news and ratings for TET and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
This page (LON:TET) was last updated on 3/28/2025 by MarketBeat.com Staff
